|
Market Closed -
Nasdaq
21:00:00 02/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.810 USD | -2.69% |
|
-7.18% | +16.03% |
| 09-16 | Novartis halts ALS drug development after mid-stage trial failure | RE |
| 09-15 | Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 3.1 | +71.27% | 5 | ||||||
| 187.07 | +11.79% | 18 | ||||||
| 1,172.36 | +27.75% | 15 | ||||||
| 688.17 | +21.67% | 23 | ||||||
| 257.47 | +24.6% | 22 | ||||||
| 288.74 | +11.82% | 19 | ||||||
| 433.52 | +21.07% | 28 | ||||||
| 267,741.48 | +46.63% | 22 | ||||||
| 49.73 | +6.77% | 24 | ||||||
| 103.17 | +20.91% | 20 | ||||||
| 197.74 | +77.95% | 23 | ||||||
| 2,453.79 | +8.72% | 15 | ||||||
| 589.92 | -1.59% | 13 | ||||||
| 1,482.61 | +27.26% | 8 | ||||||
| 273.03 | +34.85% | 20 | ||||||
| 72.01 | -3.81% | 14 | ||||||
| 53.93 | -7.63% | 15 | ||||||
| 619.67 | +31.23% | 19 | ||||||
| 305 | +5.1% | 15 | ||||||
| 70.06 | -8.58% | 18 | ||||||
| Average | 13,852.13 | +21.39% | 18 | ||||||
| Weighted average by Cap. | 15,467.73 | +20.46% | 19 |
- Stock Market
- Stocks
- ALEC Stock
- Sector Alector, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
